BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 25918286)

  • 21. Survival benefit of adjuvant chemotherapy after resection of Stage I lung adenocarcinoma containing micropapillary components.
    Li Y; Zhao J; Zhao Y; Li R; Dong X; Yao X; Xia Z; Xu Y; Li Y
    Cancer Med; 2024 Feb; 13(3):e7030. PubMed ID: 38400663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predominant histologic subtype in lung adenocarcinoma predicts benefit from adjuvant chemotherapy in completely resected patients: discovery of a holy grail?
    Russell PA; Wright GM
    Ann Transl Med; 2016 Jan; 4(1):16. PubMed ID: 26855952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological features, survival outcomes, and appropriate surgical approaches for stage I acinar and papillary predominant lung adenocarcinoma.
    Lu D; Yang J; Liu X; Feng S; Dong X; Shi X; Zhai J; Mai S; Jiang J; Wang Z; Wu H; Cai K
    Cancer Med; 2020 May; 9(10):3455-3462. PubMed ID: 32207885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma.
    Hung JJ; Wu YC; Chou TY; Jeng WJ; Yeh YC; Hsu WH
    Ann Thorac Surg; 2016 Apr; 101(4):1346-53. PubMed ID: 26794883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma.
    Murakami S; Ito H; Tsubokawa N; Mimae T; Sasada S; Yoshiya T; Miyata Y; Yokose T; Okada M; Nakayama H
    Lung Cancer; 2015 Nov; 90(2):199-204. PubMed ID: 26341957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma.
    Guo Z; Yi F; Yin W; Zhang Y; Li Q; Gu Y; Xiao Y; Cao B; Ma L; Liang L
    Thorac Cancer; 2017 May; 8(3):159-169. PubMed ID: 28220630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.
    Warth A; Muley T; Meister M; Stenzinger A; Thomas M; Schirmacher P; Schnabel PA; Budczies J; Hoffmann H; Weichert W
    J Clin Oncol; 2012 May; 30(13):1438-46. PubMed ID: 22393100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know.
    Eguchi T; Kadota K; Park BJ; Travis WD; Jones DR; Adusumilli PS
    Semin Thorac Cardiovasc Surg; 2014; 26(3):210-22. PubMed ID: 25527015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact and clinicopathological correlations of the cribriform pattern in pulmonary adenocarcinoma.
    Warth A; Muley T; Kossakowski C; Stenzinger A; Schirmacher P; Dienemann H; Weichert W
    J Thorac Oncol; 2015 Apr; 10(4):638-44. PubMed ID: 25634008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.
    Yoshizawa A; Motoi N; Riely GJ; Sima CS; Gerald WL; Kris MG; Park BJ; Rusch VW; Travis WD
    Mod Pathol; 2011 May; 24(5):653-64. PubMed ID: 21252858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
    Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
    J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of recurrence and survival of pathological T1N0M0 invasive adenocarcinoma following lobectomy.
    Wang Y; Zheng D; Zheng J; Huang Q; Han B; Zhang J; Zhao H; Chen H
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1015-1023. PubMed ID: 29532227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients.
    Sun Y; Yu X; Shi X; Hong W; Zhao J; Shi L
    World J Surg Oncol; 2014 May; 12():148. PubMed ID: 24885205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma.
    Gu J; Lu C; Guo J; Chen L; Chu Y; Ji Y; Ge D
    J Surg Oncol; 2013 Apr; 107(5):474-80. PubMed ID: 22952152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic implication of predominant histologic subtypes of lymph node metastases in surgically resected lung adenocarcinoma.
    Suda K; Sato K; Shimizu S; Tomizawa K; Takemoto T; Iwasaki T; Sakaguchi M; Mitsudomi T
    Biomed Res Int; 2014; 2014():645681. PubMed ID: 25371901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential gene expression profiles according to the Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society histopathological classification in lung adenocarcinoma subtypes.
    Molina-Romero C; Rangel-Escareño C; Ortega-Gómez A; Alanis-Funes GJ; Avilés-Salas A; Avila-Moreno F; Mercado GE; Cardona AF; Hidalgo-Miranda A; Arrieta O
    Hum Pathol; 2017 Aug; 66():188-199. PubMed ID: 28603066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Why do pathological stage IA lung adenocarcinomas vary from prognosis?: a clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification.
    Zhang J; Wu J; Tan Q; Zhu L; Gao W
    J Thorac Oncol; 2013 Sep; 8(9):1196-202. PubMed ID: 23945388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma†.
    Ito M; Miyata Y; Yoshiya T; Tsutani Y; Mimura T; Murakami S; Ito H; Nakayama H; Okada M
    Eur J Cardiothorac Surg; 2017 Feb; 51(2):218-222. PubMed ID: 28186287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of Lepidic Component Predominance to Adjuvant Chemotherapy with Oral Fluoropyrimidines for Stage I Lung Adenocarcinoma.
    Sasada S; Miyata Y; Mimae T; Tsutani Y; Mimura T; Okada M
    Clin Lung Cancer; 2016 Sep; 17(5):433-440.e1. PubMed ID: 26725850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma.
    Yanagawa N; Shiono S; Abiko M; Ogata SY; Sato T; Tamura G
    Ann Thorac Surg; 2014 Aug; 98(2):453-8. PubMed ID: 24961844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.